Researchers at UCC have developed a microneedle-based patch that results in increased vaccine-induced protection against malaria infection using lower doses of vaccine in pre-clinical testing.
The lead researcher, Dr Anne Moore, heads to Silicon Valley next week to meet venture capitalists and leading technology companies with a view to commercialising the research.
The microneedle-based patch also overcomes one of the main problems with this type of vaccine which relates to overcoming pre-existing immunity to the vaccine. The scientists combined two vaccine technologies to determine if immunity could be further enhanced and the research suggests that using a microneedle patch would overcome the need to make and use multiple different vaccine types to induce protective immunity to some of the world’s biggest killers. This could have significant consequences on the costs and logistics of vaccination.
The work was carried out by researchers in the School of Pharmacy, Dept. of Pharmacology and the Tyndall National Institute, UCC, led by Dr Anne Moore in collaboration with colleagues at the Jenner Institute, University of Oxford and was published byNature Publication Group in Scientific Reports and funded by Enterprise Ireland and Science Foundation Ireland. Dr Moore’s visit to Silicon Valley is being hosted by the Irish Technology Leadership Group (ITLG) as part of an SFI initiative for researchers to help them develop their entrepreneurial skills in the Get Started Venture Technology programme.
The skin patch has arrays of tiny silicon ‘microneedles’ that painlessly create temporary pores in the very outermost barrier layer of the skin, permitting the vaccine to flow into the skin, which is rich in cells of the immune system. The experimental vaccine was based on a live adenovirus. This virus is similar to those that can cause a common cold, but is engineered to be safer and to deliver a protein from the malaria-causing parasite, to the immune system.
The Latest on: Malaria vaccine
via Google News
The Latest on: Malaria vaccine
- The Latest: WHO official says malaria drug won't stop deathson June 26, 2020 at 6:55 am
The World Health Organization’s top scientist says it’s now been definitively proven that the cheap malaria drug hydroxychloroquine — the drug favoured by President Donald Trump — doesn’t ...
- Tomocube holotomography microscopy reveals novel cholesterol membrane transport system in erythrocytes infected with fatal malaria parasiteon June 24, 2020 at 9:15 am
The first study to elucidate the dynamics of membrane cholesterol transport in erythrocytes has been successfully concluded using holotomography microscopy.
- Global Fund COVID-19 Report: Deaths from HIV, TB and Malaria Could Almost Double in 12 Months Unless Urgent Action is Takenon June 24, 2020 at 1:17 am
A new report released by the Global Fund today estimates that countries affected by HIV, tuberculosis and malaria urgently need US$28.5 ...
- Italy to Be First Beneficiary of EU Malaria Fund: Siena-Based Achilles Vaccines srl to Receive Financing to Fight Malaria and COVID-19on June 19, 2020 at 12:37 am
The EU Malaria Fund (EUMF) yesterday presented its first investment into Achilles Vaccines srl at the premises of Fondazione Monte dei Paschi di Siena ...
- New Discovery Paves Way for Next-gen Malaria Vaccineon June 17, 2020 at 3:02 am
Scientists have developed a genetically attenuated parasite (GAP) that arrests late in the liver stage of human malaria.
- New genetically attenuated parasite gives hope for malaria vaccineon June 17, 2020 at 2:19 am
Using a genetically attenuated parasite (GAP), researchers have developed a new potential malaria vaccine that arrests at the late liver stage.
- New discovery could open door to next generation malaria vaccineon June 16, 2020 at 3:55 pm
Their findings published in JCI Insight pave the way for a novel, next generation vaccine against Plasmodium falciparum, the parasite that causes the deadliest form of malaria in humans. According to ...
- New discovery paves way for next generation malaria vaccineon June 16, 2020 at 7:28 am
In an unprecedented first, scientists at Seattle Children's Research Institute have developed a genetically attenuated parasite (GAP) that arrests late in the liver stage of human malaria. Their ...
- Here’s how a vaccine made of mosquito spit could help stop the next epidemicon June 10, 2020 at 5:00 pm
Rather than spend more years in what felt like a futile search for a malaria vaccine, she would take on all mosquito-borne pathogens at once. Her idea revolved around mosquito spit. Building on ...
- Malaria vaccines since 2000: progress, priorities, productson June 9, 2020 at 2:05 am
Malaria vaccine development entered a new era in 2015 when the pre-erythrocytic Plasmodium falciparum candidate RTS,S was favorably reviewed by the European Medicines Agency and subsequently ...
via Bing News